tiprankstipranks
Advertisement
Advertisement

COYA Stock Latest News

Coya Therapeutics reports Q2 EPS (28c), consensus (36c)
The FlyCoya Therapeutics reports Q2 EPS (28c), consensus (36c)
5d ago
COYA
Roth Capital biopharmaceuticals analyst holds a webinar
PremiumThe Fly
Roth Capital biopharmaceuticals analyst holds a webinar
1M ago
BIIB
COYA
Coya Therapeutics Shareholders Back Board, Auditor at Meeting
PremiumCompany Announcements
Coya Therapeutics Shareholders Back Board, Auditor at Meeting
2M ago
8K
COYA
Coya Therapeutics initiates first cohort of patients in ALSTARS trial
PremiumThe Fly
Coya Therapeutics initiates first cohort of patients in ALSTARS trial
2M ago
COYA
Coya Therapeutics initiated with a Buy at Roth Capital
PremiumThe Fly
Coya Therapeutics initiated with a Buy at Roth Capital
2M ago
COYA
Coya Therapeutics Establishes $30 Million ATM Equity Program
PremiumCompany AnnouncementsCoya Therapeutics Establishes $30 Million ATM Equity Program
3M ago
8K
COYA
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
Premium
Company Announcements
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
3M ago
8K
COYA
Coya Therapeutics granted FDA Fast Track Designation for COYA 302
Premium
The Fly
Coya Therapeutics granted FDA Fast Track Designation for COYA 302
3M ago
COYA
Coya Therapeutics reports Q1 EPS (32c), consensus (39c)
PremiumThe Fly
Coya Therapeutics reports Q1 EPS (32c), consensus (39c)
3M ago
COYA
Coya Therapeutics announces publication of research on COYA 302
PremiumThe Fly
Coya Therapeutics announces publication of research on COYA 302
4M ago
COYA
Coya Therapeutics Announces Leadership Changes and New Director
PremiumCompany Announcements
Coya Therapeutics Announces Leadership Changes and New Director
5M ago
8K
COYA
Coya Therapeutics Executive Chairman Howard Berman steps down
PremiumThe Fly
Coya Therapeutics Executive Chairman Howard Berman steps down
5M ago
COYA
3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
5M ago
COYA
CTMX
Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating
Premium
Ratings
Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating
5M ago
COYA
Coya publishes study showing reduction in regulatory T cell function in FTD
Premium
The Fly
Coya publishes study showing reduction in regulatory T cell function in FTD
5M ago
COYA
Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD
PremiumRatings
Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD
5M ago
COYA
Coya Therapeutics Announces Strategic Private Placement Financing
PremiumCompany Announcements
Coya Therapeutics Announces Strategic Private Placement Financing
7M ago
8K
COYA
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
PremiumThe Fly
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
7M ago
RDY
COYA
Coya Therapeutics Reports Strong Cash Position and Runway
PremiumCompany Announcements
Coya Therapeutics Reports Strong Cash Position and Runway
7M ago
8K
COYA
COYA-302: De-Risked Treg Platform With Compelling FTD Data and ALS Phase 2 Catalyst Supporting Buy Rating
PremiumRatingsCOYA-302: De-Risked Treg Platform With Compelling FTD Data and ALS Phase 2 Catalyst Supporting Buy Rating
7M ago
COYA
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating
Premium
Ratings
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating
7M ago
COYA
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data
Premium
Company Announcements
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data
7M ago
8K
COYA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >